Study S001103

A Trial to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.0 mg/mL

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04228354
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 28
Start: 2020-01-29
Primary completion: 2020-06-01
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers; Overweight; Obesity
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1241-6257; REGISTRY:2019-004020-37; NIH:2019

Registered primary outcomes

Area under the semaglutide plasma concentration curve from 0 to tz [0-840 hours]
Maximum semaglutide plasma concentration [0-840 hours]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.